Overgewicht/obesitas Obesity overweight
Conditions
Interventions
Two treatments will be supplied for three weeks, with a wash-out period of at
least 3 weeks in-between.
Two treatments will be given: three weeks with a fat supplement containing long
chain fatty a
Sponsors
TNO
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Healthy as assessed by the health and lifestyle questionnaire, physical examination and results of the pre-study laboratory tests; 2. Males aged between 30 - 60 years at Day 01 of the study; 3. Overweight/obese subjects, Body Mass Index (BMI) between 27-35 kg/m2 ; 4. Range in waist-hip ratio as high as possible (preferably below 0.90 or above 0.95); 5. Regular Dutch eating habits as assessed by P7261 F02 and used to consume margarine; 6. Non restrained eater, defined as a score of
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study; 2. Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances; 3. Having a history of medical or surgical events that may significantly affect the study outcome, including any psychiatric history, and metabolic or endocrine disease, or any gastro-intestinal disorder; 4. Use of medication that may influence appetite, and/or sensory functioning within 14 days before day 01, except paracetamol; 5. Smoking; 6. Alcohol consumption (> 28 units/week); 7. Contra-indication to MRI scanning (claustrophobia; pacemakers and defibrillators; nerve stimulators; intracranial clips; intraorbital or intraocular metallic fragments; cochlear implants; ferromagnetic implants; presence of any other metal object e.g. in the mouth); 8. Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening; 9. Reported slimming or medically prescribed diet; 10. Reported vegan, vegetarian or macrobiotic; 11. Recent blood donation (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints: On the last day (day 21 and day 63) of each treatment period subjects will come to the metabolic ward of TNO for evaluation of the effect of the dietary intervention on fat metabolism and fat tissue. This will be examined with stable isotope techniques and fat biopsies of subcutaneous fat. The primary objective of the study is to investigate the effect of chain length of the fatty acid consumed on kinetics of fat metabolism and fat disposition (centrally or subcutaneously). | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. leucine tracers in blood as a measure for lipoprotein synthesis and degeneration ; 3. changes in fat tissue characteristue due to the intervention; 4. satiety hormones and scores. | — |
Countries
Netherlands
Outcome results
None listed